Components of the Biochemistry Core (Core B) detailed in this section of the grant include automated assays for inhibitor screening, cloning and expression of target enzymes, and immunolocalization protocols for both proteases and endogenous inhibitors. We recognize that there may be variation in the type of protease expressed by different tumors, or multiple proteases may be produced by the same tumor. To gain a perspective on protease variation within individual tumors, and to ensure all key targets are examined, we will screen each of our human epithelial cancer tissue banks for proteolytic activity. Automated protease assays will allow detection of individual classes of enzymes in each tumor sample. This screen should provide information on whether certain tumor types will require more than one class-specific inhibitor and whether we should consider targeting other proteases (e.g. cathepsin D, cathepsin L, or other metalloproteases). The automated assays we will use for this retrospective screening of tumor tissue banks may later serve as diagnostic assays to direct inclusion of class-specific inhibitors as adjuvant therapy in individual patients. The Biochemistry Core will also screen tumor cell lines developed and used by the Cell Biology and confirm protease or inhibitor expression for the Transgenic Core (Core C). By comparison to the relevant human cancer tissue bank, the cell lines which best reflect protease expression in actual tumor samples can be identified. Proteases (and, if relevant, protein inhibitors) will be localized by immunohistochemistry or active site-directed biotinylated probes. If any variants of known proteases are identified as having altered substrate specificity or localization, they will be further analyzed by PCR amplification and sequencing. Finally, when tumor samples and cell lines are assayed, aliquots will be provided to Project 3 for assays of multidrug transporter, P-glycoprotein, cytochrome P450s, glutathione-S-transferases and epoxide hydrolases.
| Sathler, Plinio Cunha; Lourenco, Andre Luiz; Miceli, Leonardo Alves et al. (2014) Structural model of haptoglobin and its complex with the anticoagulant ecotin variants: structure-activity relationship study and analysis of interactions. J Enzyme Inhib Med Chem 29:256-62 |
| LeBeau, Aaron M; Duriseti, Sai; Murphy, Stephanie T et al. (2013) Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res 73:2070-81 |
| Darragh, Molly R; Schneider, Eric L; Lou, Jianlong et al. (2010) Tumor detection by imaging proteolytic activity. Cancer Res 70:1505-12 |
| Sounni, Nor E; Dehne, Kerstin; van Kempen, Leon et al. (2010) Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech 3:317-32 |
| Littlepage, Laurie E; Sternlicht, Mark D; Rougier, Nathalie et al. (2010) Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 70:2224-34 |
| Kessenbrock, Kai; Plaks, Vicki; Werb, Zena (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67 |
| Lederle, Wiltrud; Hartenstein, Bettina; Meides, Alice et al. (2010) MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 31:1175-84 |
| Barkan, David T; Hostetter, Daniel R; Mahrus, Sami et al. (2010) Prediction of protease substrates using sequence and structure features. Bioinformatics 26:1714-22 |
| Sun, Cheng; Su, Kai-Hung; Valentine, Jason et al. (2010) Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS Nano 4:978-84 |
| Andreu, Pauline; Johansson, Magnus; Affara, Nesrine I et al. (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121-34 |
Showing the most recent 10 out of 134 publications
